Navigation Links
OncoGenex to Report Financial Results for Third Quarter 2013 and Address Key Questions from Investors on November 7, 2013
Date:10/30/2013

ormation from the quarterly call by following the new OncoGenex Investor Relations Twitter account at: http://twitter.com/@OncoGenex_IR

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our expected timelines for our SYNERGY and Borealis-1 trials. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
2. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
3. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
4. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
5. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
6. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
8. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
9. Hanger Reports Third Quarter 2013 Results
10. Covance Reports Third Quarter Net Revenue Of $607 Million, Pro Forma EPS Of $0.83 And Adjusted Net Orders Of $732 Million
11. Questcor Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... FORT LAUDERDALE, Fla. , July 2, 2015 ... & Co., is pleased to announce that its ... Inc. ("Insight Beverages") to Kerry Group plc (ISE: ... focused on taste and nutrition systems, as well ... food, beverage and pharmaceutical markets. Farlie Turner served ...
(Date:7/2/2015)... July 2, 2015 Releases of ... Aedes aegypti , , reduced the dengue ... Brazil by 95%, well below the modelled ... http://photos.prnewswire.com/prnh/20150630/227348LOGO) , The journal PLOS Neglected Tropical ... Oxitec,s genetically engineered mosquitoes. The results showed that in ...
(Date:7/2/2015)... According to a new market research report " ... Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, Tinnitus, Alzheimer,s, Epilepsy, Ischemia, ... the global Neuromodulation Market is estimated at $3.65 Billion in ... at a CAGR of 11.2% during the forecast period. ... market data T ables and 32 ...
Breaking Medicine Technology:Farlie Turner's Consumer Group Completes Sale of Insight Beverages to Kerry 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4
... Globus Medical, Inc., the largest,privately held spinal ... in motion preservation technology, today announced the completion ... study. The,SECURE(R)-C device is designed to mimic the ... pain and restore function as an alternative to ...
... Siemens Healthcare and,Laboratory Corporation of America(R) Holdings ... non-exclusive agreement to discuss future,possibilities to co-develop ... of,companion diagnostics, metabolic syndrome, oncology and diabetes. ... developing new tests that,could make the biggest ...
Cached Medicine Technology:Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4
(Date:7/4/2015)... ... , ... When a hacker gains access to someone’s email account, it can lead to all ... 1st, the FTC issued a scam alert about a social engineering scam which ... password reset instigated by the hacker. All they have to do is click for ...
(Date:7/3/2015)... Angeles, CA (PRWEB) , ... July 03, 2015 ... ... was opened for enrollment on July 2nd creating a buzz of media attention. ... has been published online by HonestyFirstReviews.com's Tiffany Hendricks. , "These days many people ...
(Date:7/3/2015)... ... ... Scientists at several top US cancer centers believe they now know why certain ... to read the complete story , just posted on the Surviving Mesothelioma website. ... New York University exposed mice with a mutation on the tumor suppressor gene called ...
(Date:7/3/2015)... , ... July 03, 2015 , ... ... to healthcare providers, has been retained to lead a national chief nursing ... the top-ranked executive search firms in the healthcare industry, B. E. Smith has ...
(Date:7/3/2015)... ... July 03, 2015 , ... Talcum powder attorneys representing ... their existing Talcum Powder Cancer Lawsuit Center website. Just as the previous version did, ... news , offering timely lawsuit updates and ovarian cancer warning information. The site is ...
Breaking Medicine News(10 mins):Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 3Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 4Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3
... have identified childhood cancer survivors who are at ... due to the lifesaving bone marrow transplants they ... need for long-term monitoring and early intervention, particularly ... education, researchers said. Among the measures investigators recommend ...
... WASHINGTON, D.C. A scientifically-based tool developed by researchers ... women prevent pregnancy naturally, is now being used by ... An estimated twenty percent of women who wish ... know when they are fertile, according to the American ...
... ... the Socially Responsible (SRI) Bullion Fund Deploy Equity Long/Short Strategy with Apple ... companies with good bottom up fundamentals and sell closely related companies that ... to the overall markets. In this case, we go long an equally ...
... ... #1 brand in designer fashion shaping swimwear, has launched a line ... shaping construction. In launching this new collection, Miraclebody® announces a ... who can nominate themselves or others, this contest will honor and ...
... when green-eyed monster took over, study found , THURSDAY, April ... jealousy, according to a new study. , Researchers had heterosexual ... was told to look for pictures of landscapes amid rapidly ... upsetting image. , At the same time, her male partner ...
... ... ... Genesys Physician Hospital Organization (PHO) was faced with the challenging decision of building a ... careful cost analysis and evaluation of possible data centers, Genesys PHO choose colocation with ...
Cached Medicine News:Health News:Research findings underscore needed action to safeguard lungs of young cancer survivors 2Health News:Research findings underscore needed action to safeguard lungs of young cancer survivors 3Health News:Getting the bead on conception 2Health News:Getting the bead on conception 3Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 2Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 3Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 4Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 5Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 6Health News:Innovative Patent-pending Shapewear Technology Introduced for Jeans. 2Health News:Genesys PHO Outsources Data Center to Online Tech 2Health News:Genesys PHO Outsources Data Center to Online Tech 3Health News:Genesys PHO Outsources Data Center to Online Tech 4
... more comfortable, and you will too., ... and to avoid the knotty problems associated ... ties, consider the Dale® Tracheostomy Tube Holder. ... narrow fastener tabs of the Dale® Tracheostomy ...
... securely in place. Soft strap features an ... Soft compliant foam laminate with elastic adjustment ... edema while still providing a snug fit. ... helps prevent sliding and patient irritation, and ...
... Percutaneous Dilation Tracheostomy Kits allow ... tracheostomy tube using the widely ... of a single-stage curved dilator. ... without the Portex® Blue Line ...
... Self-contained kits provide convenience and cost control. ... care trays offer a variety of wound ... management of the tracheostomized patient. , ... and trays with disposable inner cannula for ...
Medicine Products: